New Treatments for Recurrent Uterine Cancer

[1]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[2]  D. Cella,et al.  Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Cimino-Mathews,et al.  Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. , 2020, Gynecologic oncology.

[4]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis , 2020, Clinical Cancer Research.

[5]  Y. Bang,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.

[6]  E. Schmidt,et al.  Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Vergote,et al.  Second-line lenvatinib in patients with recurrent endometrial cancer. , 2020, Gynecologic oncology.

[8]  G. Scambia,et al.  Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment , 2019, International Journal of Gynecological Cancer.

[9]  Annie Y. Liu,et al.  Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. , 2019, Gynecologic oncology.

[10]  S. J. Henley,et al.  Uterine Cancer Incidence and Mortality — United States, 1999–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[11]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[12]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[14]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[15]  H. Rugo,et al.  Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Park,et al.  Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement , 2024, Journal of gynecologic oncology.

[17]  R. Lifton,et al.  Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab , 2016, Clinical Cancer Research.

[18]  Gyan Bhanot,et al.  Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. , 2016, The Journal of clinical investigation.

[19]  M. Kloor,et al.  The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.

[20]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[21]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[22]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[23]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[24]  Scott D. Brown,et al.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.

[25]  Masao Iwata,et al.  Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. , 2013, Cancer letters.

[26]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[27]  A. Ashworth,et al.  Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.

[28]  R. Stone,et al.  Factors associated with Type I and Type II endometrial cancer , 2010, Cancer Causes & Control.

[29]  J. García,et al.  Novel molecular profiles of endometrial cancer—new light through old windows , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  Yuji Yamamoto,et al.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.

[31]  G. Fleming,et al.  Chemotherapy in endometrial cancer. , 2006, Clinical advances in hematology & oncology : H&O.

[32]  T. Oliver,et al.  Follow-up after primary therapy for endometrial cancer: a systematic review. , 2006, Gynecologic oncology.

[33]  N. Sneige,et al.  Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[35]  G. Parham,et al.  Overexpression of HER-2/neu in uterine serous papillary cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  E. Sartori,et al.  Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy , 2001, International Journal of Gynecologic Cancer.

[37]  T. Honjo,et al.  PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. , 2001, Trends in immunology.

[38]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[40]  Y. Shiloh,et al.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. , 1988, Cancer research.

[41]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[42]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[43]  R. Weinberg,et al.  Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas , 1982, Cell.

[44]  H.J.M.M. Mertens,et al.  Factors predicting recurrent endometrial cancer , 2013, Facts, views & vision in ObGyn.

[45]  J. Berek,et al.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[46]  O. Fadare,et al.  Insights into endometrial serous carcinogenesis and progression. , 2009, International journal of clinical and experimental pathology.

[47]  R. Reznek,et al.  Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. , 2007, Clinical radiology.

[48]  V. Abeler,et al.  Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients. , 1984, Gynecologic oncology.